Development of an Inactivated Vaccine against SARS CoV-2
| Autor: | Hazel Yetiskin, Ahmet Furkan Aslan, Shaikh Terkis Islam Pavel, Busra Kaplan, Aykut Ozdarendeli, Gunsu Aydin, Muhammet Ali Uygut, Öznur İnan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
ERUCoV-VAC Immunology immunogenicity Article Viral vector Immune system vaccine Drug Discovery Pandemic Medicine Pharmacology (medical) Pharmacology business.industry SARS-CoV-2 Immunogenicity Outbreak inactivated vaccine Virology Clinical trial Infectious Diseases TURKOVAC Inactivated vaccine business COVID-19 vaccine |
| Zdroj: | Vaccines Volume 9 Issue 11 Vaccines, Vol 9, Iss 1266, p 1266 (2021) |
| ISSN: | 2076-393X |
| Popis: | The rapid spread of SARS-CoV-2 with its mutating strains has posed a global threat to safety during this COVID-19 pandemic. Thus far, there are 123 candidate vaccines in human clinical trials and more than 190 candidates in preclinical development worldwide as per the WHO on 1 October 2021. The various types of vaccines that are currently approved for emergency use include viral vectors (e.g., adenovirus, University of Oxford/AstraZeneca, Gamaleya Sputnik V, and Johnson & Johnson), mRNA (Moderna and Pfizer-BioNTech), and whole inactivated (Sinovac Biotech and Sinopharm) vaccines. Amidst the emerging cases and shortages of vaccines for global distribution, it is vital to develop a vaccine candidate that recapitulates the severe and fatal progression of COVID-19 and further helps to cope with the current outbreak. Hence, we present the preclinical immunogenicity, protective efficacy, and safety evaluation of a whole-virion inactivated SARS-CoV-2 vaccine candidate (ERUCoV-VAC) formulated in aluminium hydroxide, in three animal models, BALB/c mice, transgenic mice (K18-hACE2), and ferrets. The hCoV-19/Turkey/ERAGEM-001/2020 strain was used for the safety evaluation of ERUCoV-VAC. It was found that ERUCoV-VAC was highly immunogenic and elicited a strong immune response in BALB/c mice. The protective efficacy of the vaccine in K18-hACE2 showed that ERUCoV-VAC induced complete protection of the mice from a lethal SARS-CoV-2 challenge. Similar viral clearance rates with the safety evaluation of the vaccine in upper respiratory tracts were also positively appreciable in the ferret models. ERUCoV-VAC has been authorized by the Turkish Medicines and Medical Devices Agency and has now entered phase 3 clinical development (NCT04942405). The name of ERUCoV-VAC has been changed to TURKOVAC in the phase 3 clinical trial. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|